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ABSTRACT 
The effect of pretreatment with 3-deazauridine 
(DAU) and pyrazofurin(PF), alone or in sequence, on the 
uptake, metabolism, and in vitro cytotoxicity of cytosine 
arabinoside(Ara-C) was studied in murine(L1210) and human 
(HL-60) leukemic cells, PF and DAU block synthesis of CTP 
at different steps of the pyrimidine biosynthetic pathway. 
Pretreatment with either agent alone for three hours at 
5^M better than halved the expected cell survival following 
one hour of 5^M Ara-C in L1210. In HL-60 such pretreatment 
resulted in only marginally better than additive cytotoxi¬ 
city with 3/jM Ara-C(l hour), and PF pretreatment was as 
effective as DAU pretreatment at reducing cell survival 
despite the fact that the latter significantly increased 
Ara-C uptake and Ara-CTP formation while the former had 
no effect on total Ara-C uptake and actually depressed 
Ara-CTP levels. 
Pretreatraent with both PF and DAU, in either se¬ 
quence, resulted in almost total cell kill in L1210 cells 
exposed to 2/xM or 5/<M Ara-C for one hour. When the Ara-C 
exposure precedes PF and DAU,.synergy is still noted in 
these cells, but it is an order of magnitude smaller. In 
HL-60, pretreatment with both drugs results in marked sy¬ 
nergy with Ara-C cytoxicity (3^*M Ara-C for 1 hour). Greater 
cytotoxic synergy was evident when PF exposure preceded DAU 
exposure than when DAU was administered first, even though 
the latter resulted in a significantly higher rate of Ara-C 
uptake. In addition, HL-60 cells pretreated with both PF 
and DAU, in either order, had Ara-CTP levels no higher than 
cells exposed to Ara-C without pretreatment. The key to 
understanding the synergy exhibited between the pretreat¬ 
ment regimes and Ara-C is the linear relationship between 
the Ara-CTP/CTP ratio and clone survival. At the concen¬ 
trations and durations of exposure studied, PF depleted 
cellular CTP to a much greater degree than DAU, and the 
combination of the two, especially when PF exposure is 
first, further depleted CTP. Ara-CTP formation is apparently 
influenced by the level of UTP as well as the level of 
dCTP, and the fraction of Ara-C taken up that is converted 
to Ara-CTP may depend on the relative concentrations of the 
pyrimidine nucleotides. These findings may be helpful for the 
evaluation of other pretreatment regimes designed to en¬ 
hance Ara-C cytoxicity. Further studies are necessary to 
define the possible utility of the PF/DAU/Ara-C combination. 
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I. INTRODUCTION 
Two relatively recent developments in the design 
of antineoplastic chemotherapy are the concept of malignant 
transformation-linked enzymic alterations and the use of 
deductive, as opposed to empiric, reasoning to construct 
drug combination regimes. The former arises from obser¬ 
vations like those of Geoge Weber and his co-workers (111, 
112,113,115) that malignant neoplasms of varying origins 
exhibit elevated activities of a number of key enzymes and 
their products and that the height of those elevations can, 
to a certain extent, be correlated with growth rates in a 
series of tumors. The recognition and control of such en¬ 
zymes and their products may well be the key to treating 
neoplasia. The latter is exemplified by the use of an agent 
to deplete the cell of a vital molecule before administra¬ 
tion of a drug whose toxic effect is exerted in competition 
with that compound. This project applies both approaches 
to the design and study of a novel combination of antineo¬ 
plastic drugs and studies them in murine (L1210) and human 
(HL-60) leukemic cells. 
One of the raaj or targets for chemotherapeutic 
agents has been the synthesis of deoxyribonucleotides, 
based on the increased need of rapidly dividing cells, 
as opposed to normal tissue, for DNA precursors. Notable 
among the enzymes found elevated in a variety of tumors 
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are a large number of the enzymes involved in pyrimidine 
biosynthesis and salvage, and levels of pyrimidine ribo- 
and deoxyribonucleotides are elevated as well (111,113, 
115). Pyrimidine catabolic pathways are, on the other hand, 
depressed in neoplasia. 
Cytosine arabinoside(Ara-C, Cytarabine, 1-beta- 
D-arabinofuranosylcytosine) is a cytosine analog which at 
present is a major agent used in the treatment of acute 
myeloid leukemia in adults and being studied for use in 
combination with agents in a number of other tumors (94), 
but whose clinical utility is limited by rapid detoxifi¬ 
cation and emergence of resistant clones. It acts by in¬ 
hibiting DNA synthesis, via direct incorporation into DNA 
and/or inhibition of DNA polymerase, in competition with 
the natural substrate dCTP. 3-Deazauridine(DAU, 1-beta-D- 
ribofuranosyl-2,4-pyridinedione) is a structural analog of 
uridine which competitively inhibits cytidine triphosphate 
synthetase, the enzyme which converts UTP to CTP. By depleting 
cellular CTP and, presumably, dCTP, it removes feedback in¬ 
hibition of deoxycytidine kinase, the enzyme responsible 
for phosphorylating, and thus activating, Ara-C; it may 
also inhibit Ara-C deamination(detoxification) by feedback 
inhibition of cytidine deaminase. Thus, despite modest anti¬ 
tumor effect of its own, there is reason to expect that it 
could enhance the toxicity of Ara-C, and perhaps act on 
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Ara-C resistant mutants who relied entirely on de novo 
pyrimidine synthesis. However, DAU limits its own toxi¬ 
city in two ways. First, build-up of UTP behind the com¬ 
petitive block could lead to break-through CTP synthesis. 
Second, UTP excess would inhibit uridine kinase, the 
enzyme resposible for transformation of DAU to its active 
form. 
Pyrazofurin(PF,4-hydroxy-5-beta-D-ribofuranosyl- 
pyrazole-3-carboximide) is a C-nucleoside analog which 
strongly inhibits orotidylate decarboxylase, the enzyme 
responsible for UMP production from orotidylate 5*-mono- 
phosphate. This agent thus blocks de novo synthesis of 
pyrimidines, and the resultant UTP and CTP depletion could, 
as with DAU, be expected to enhance Ara-C toxicity. How¬ 
ever, PF is incapable of blocking uridine re-utilization, 
a major source of pyrimidines in some cell lines and, pre¬ 
sumably, in some human tumors, expecially those derived from 
cells which import much of their pyrimidines. Perhaps the 
combination of PF and DAU, blocking both de novo and salvage 
pathways, and preventing UTP build-up and subversion of 
DAU inhibition of cytidine triphosphate synthetase, could 
enhance Ara-C cytotoxicity more than either alone. Ihis pro¬ 
ject investigates the effects of DAU and PF pretreatment on 
the uptake, metabolism, and toxicity of Ara-C in L1210 and 
HL-60 cells. 
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A. Pyrimidine Nucleotides; Biosynthesis« Interconversion. 
and Control Mechanisms 
Before discussing the effects of the agents 
being studied, it is in order to review briefly pyrimi¬ 
dine biosynthesis, the interconversions by which uridine 
5 *-monophosphate(UMP) is transformed into the other py¬ 
rimidine nucleotides, and the mechanisms which control 
these processes. Excellent reviews of recent advances 
in our understanding of pyrimidine biosynthesis and meta¬ 
bolism are available (51,69,99), and the readers are re¬ 
ferred to them for a more detailed discussion and biblio¬ 
graphy. 
1. Biosynthesis 
The pathways by which UMP is synthesized and 
converted to cytidine and thymidine nucleotides as well 
as its own are illustrated in Figure 1. De novo biosynthesis 
of UMP begins with the formation of carbamyl phosphate by 
carbamyl phosphate synthetase-II(CPS-II). In contrast to 
mitochondrial carbamyl phosphate synthetase-I, which uti¬ 
lizes ammonia as a nitrogen source for the urea-synthetic 
pathway, cytoplasmic CPS-II utilizes glutamine as its 
normal nitrogen source as indicated by enzyme kinetics 
(reviewed in (69)). Carbamyl phosphate is combined with 
aspartate to form carbamyl aspartate, a reaction catalyzed 
by aspartate transcarbamylase (ATC), which is then converted 
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to dihydoorotic acid by dihydroorotase(DHO)• Since CPS-II, 
ATC, and DHO can be co-purified on column chromatography 
of tissue fractions, it has been suggested that these three 
enzymes exist in cells as a multifunctional complex (re¬ 
viewed in (99)), perhaps providing a channeling of product 
to assist separation of mitochondrial and cytoplasmic 
carbarayl phosphate pools, 
Dihydroorotic acid is oxidized to orotic acid 
by dihydroorotic acid dehydrogenase(DHOD), which, in con¬ 
trast to the other enzymes of the de novo pathway, appears 
to be associated with cellular membranes (reviewed in (99)), 
The orotic acid is combined with 5-phosphoribosyl pyrophos- 
phate(PRPP) by orotate phosphoribosyl transferase(OPRT) to 
form orotidine 5'-monophosphate(OMP), OPRT exists as a 
cytoplasmic complex with the final de novo pathway enzyme, 
orotidylate decarboxylase(OTD), which catalyzes the ir¬ 
reversible decarboxylation of OMP to produce UMP, 
Regulation of the de novo pathway (see Table 1) 
is primarily directed at the initial step, the formation of 
carbamyl phosphate from glutamine, bicarbonate, and ATP 
by CPS-II, This is present at lower activity than the other 
enzymes in its cluster in a number of tissues studied, 
as presented by Moyer (80), and the presence of UTP, an 
ultimate product of the pathway, inhibits the enzyme, ap¬ 
parently acting in an allosteric fashion by decreasing its 
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affinity for ATP, the only substrate not present in excess, 
by as much as a factor of ten (69,80). PRPP, on the other 
hand, has been shown to increase the affinity of CPS-II 
for ATP, thus enhancing its activity (reviewed in (99)). 
Stimulated cells, such as phytohemaglutinin(PHA)-stimulated 
human lymphocytes and isoproterenol-stimulated salivary 
glands, have elevated CPS-II activities, and CPS-II activity 
has been correlated with the mitotic index in normal tis¬ 
sues and growth rates of a series of tumors (reviewed in 
(69)). To a lesser extent, PRPP may activate the activity 
of OPRT, and both UMP and cytidine 5’-monophosphate(CMP) 
inhibit OTD, though the usually low levels of the mono¬ 
phosphates and the relatively high inhibition constants 
for them make this unlikely to be an important regulatory 
mechanism (69). 
2. Interconversion 
Synthesis of cytidine and deoxycytidine nucleo¬ 
tides from UMP begins with the production of UTP by the 
action of nucleoside monophosphate kinase(NMK) and nucleo¬ 
tide diphosphate kinase(NDK), enzymes of high activity (49) 
that provide for rapid equilibrium of mono-, di-, and tri¬ 
phosphate nucleotide pools, with the triphosphates the pre¬ 
dominant form unless cellular energetics are compromised 
(80). Cytidine triphosphate synthetase(CTS) then catalyzes 
the transformation of UTP to CTP, from which the other 
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cytidine ribonucleotides are derived. CDP is the substrate 
from which ribonucleotide reductase(RR) produces deoxycy- 
tidine 5’-diphosphate(dCDP), which NDK phosphorylates to 
produce dCTP, the form used in DNA synthesis. Removal of 
phosphate groups from dCDP, by deoxycytidylate kinase (DCK^) 
and deoxycytidine kinase (DCK^), results in the formation 
of dCMP and deoxycytidine(CdR), respectively. 
Thymidine nucleotides are produced by the action 
of thyraidylate synthetase(TS) on deoxyuridine 5*-monophos- 
phate(dUMP). dUMP can be formed by two pathways. dUDP formed 
by the action of RR on UDP is dephosphorylated by thymidy- 
late kinaseCTK^) to dUMP. Alternately, dCMP can be directly 
converted to dUMP by deoxycytidylate deaminase(DCA^)• A 
recent study by Jackson (61) suggests that the latter path¬ 
way is the major source of dUMP in mammalian cells, the 
impact of which will be considered below. converts dTMP 
to dTDP, then NDK catalyzes the formation of dTTP. 
3. Salvage and Uptake 
Pyrimidine nucleotides can also be generated by 
salvage of free nucleosides within the cell or in the ex¬ 
tracellular space or from intracellular uracil, as illus¬ 
trated in Figure 1. Uridine phosphorylase(UP) catalyzes 
the reaction between uracil and ribose-l-phosphate to 
form uridine. Cytidine and uridine are phosphorylated by 
uridine kinase(UK), also known as uridine-cytidine kinase, 
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to CMP and UMP. Deoxyuridine(UdR) and thymidine(TdR) are 
converted to dUMP and dTMP by thymidine kinase(TK^), and 
CdR is converted to dCMP by DCK^. 
In a review of pyrimidine transport in animal 
cells, Berlin and Oliver(6) discuss transport mechanisms 
for nucleosides, which must be differentiated from uptake 
as used later in this paper. The latter term refers to 
total accumulation of a substance and its metabolites; 
in the case of nucleosides these would be the nucleotides 
formed rapidly under most metabolic conditions. Transport 
refers to intracellular accumulation of a substance in the 
absence of conversion which would maintain the diffusion 
gradient between extra- and intracellular compartments. 
For nucleosides measurement of transport rates requires 
cells deficient in the phosphorylating enzyme or cells 
depleted of ATP. Under such conditions, Berlin and Oliver 
discuss evidence that at low extracellular substrate con¬ 
centrations transport of nucleosides is a saturable, non- 
accumulative, temperature-dependent process, suggesting 
carrier-mediated facilitated diffusion, while at high 
extracellular nucleoside concentrations uptake is propor¬ 
tional to concentration and only weakly temperature-de- 
pendent, suggesting simple diffusion (6). Both processes 
are inhibited by other nucleosides, but not by free bases, 
sugars, or amino acids. Nucleoside analogs with ionized, 
but not uncharged, substituents on the base moiety or the 
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replacement of ribose with sugars other than arabinose 
reduce affinity for the low concentration carrier (reviewed 
in (6)). Plagemann et. al^(86) have recently shown that in 
Novikoff rat hepatoma cells transport of CdR and Ara-C is 
so rapid to equilibrate intra- and extracellular concen¬ 
trations within less than one minute, as they had previously 
shown for adenosine, thymidine, and uridine (reviewed in 
(6)). The rates of transport were 1-2 orders of magnitude 
higher than the rates of phosphorylation, suggesting that 
the latter is the limiting step in uptake (86). 
4. Regulation of Interconversion and Salvage 
Regulation of the enzymes involved in pyrimidine 
nucleotide intercoversions and re-utilization of nucleosides 
described above is complex and incompletely understood. Ef¬ 
fects of nucleotides themselves studied to date are presented 
in Table 1. 
Table 1: Regulation of Pyrimidine Synthetic Enzymes 
Enzyme Urd UMP UTP PRPP CTP dCTP dTTP ATP dATP 
CPS-II - + 
OPRT * 
OTD 
RR + 
CD 
DCA - + 
DCK^ + +@ 
CTS 1 
TK 
UK _ 
(+) Activated by increased levels 
(-) Inhibited by increased levels 
@ See Text 
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The best studied of these is dTTP. As reviewed by 
Harrap and Renshaw (51), dTTP restricts its own biosynthesis 
by allosteric inhibition of three enzymes. Salvage of thy¬ 
midine and deoxyuridine is inhibited via inhibition of TK^. 
By inhibiting RR, which catalyzes both the reduction of 
UDP to dUDP and CDP to dCDP, dTTP affects both pathways 
for dUMP production. This inhibition also explains the de¬ 
cline in dCTP levels and commensurate increase in CdR up¬ 
take noted by Grant et a_l.(46) after thymidine exposure. 
It also explains the phenomenon of CdR-reversible thymidine 
toxicity (61,70). The pathway to dUMP from CDP is also in¬ 
hibited by dTTP via inhibition of DO^. It is interesting 
that TS, target for pyrimidine analogues, such as 5-fluoro- 
deoxyuridylate, and antifolates, which limit dTMP production 
by depletion of the carbon group donor, is not subject to 
short-term regulation by thymidine nucleotides (61). 
DCK^, the best studied of the cytidine pathway en¬ 
zymes by virtue of its role in Ara-C activation(see next sec¬ 
tion), is inhibited by dCTP and, to a lesser extent, dCMP, 
dCDP, UDP, CDP, and dTDP (60), while it is stimulated by 
dUTP and UTP. The action of dTTP on DCK^ is complex. At 
low levels, dTTP stimulates the enzyme, reversing dCTP in¬ 
hibition at relatively low levels of dCTP. At higher nucleo¬ 
tide concentrations, dTTP replaces the dCTP effect as the 
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major source of DCK^ inhibition (60). dCTP also restricts 
its own synthesis via feedback inhibition of RR. Evidence 
for CTS inhibition by dTTP in E. coli has been presented 
(as referred to in (61)), but it is not known whether this 
control ooerates in mammalian cells. Further control of 
RR is exerted by ATP and dATP, higher ratios of which acti¬ 
vate the enzyme (61). Finally, a recent study by Drake 
et al.(35) suggested that CD and DCA^ are inhibited by 
their products, uridine and dUMP, respectively, and analogs 
of those products, esoecially DAU and DAU-MP. 
A number of authors have shown that the activities 
of many enzymes involved in dNTP synthesis increase at the 
onset of S phase, notably TK^, TK^, DCK^, and DCA^ (reviewed 
in (51)). Mitotically-selected or isoleucine-synchronized 
Chinese hamster cells that had been transformed by a virus 
demonstrated an expansion of dNTP pools, usually very small 
relative to NTP pools, during S phase, with the level of 
dCTP corresponding most closely with DNA synthesis (see 
(51)). Transport rates for nucleosides also rise signifi¬ 
cantly from to S, then fall into (6). The concentra¬ 
tion of maximal transport (K ) remains the same with in- 
ra 
creases in V^, the maximum rate of transport, most likely 
due to enhanced phosphorylation (as discussed in (6)). 
PHA-stimulated human lymphocytes exhibit an in¬ 
crease in re-utilization pathway enzymes, uridine and thy- 
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midine kinases, followed by stimulation of de novo bio¬ 
synthetic pathway enzymes (69). Finally, as noted above, 
Weber and co-workers (111,115) have studied pyrimidine 
pathway enzymes in normal liver and a variety of hepatomas 
with different growth rates. They have noted increases in 
most of the de novo and salvage pathway enzymes and cor¬ 
responding decreases in pyrimidine catabolic enzymes. In 
particular, they have reported a correlation between the 
activities of certain enzymes, most notably TK^, TK^, 
DCA^, and CTS, and the growth rates of the tumors studied. 
Although it is intuitively obvious that rapidly dividing 
cells require more deoxyribonucleotides, the pivotal roles 
of dCTP and dTTP, as discussed above, should be evident as 
we proceed to the discussion of Ara-C, DAU, and PF toxicity. 
* 
* 
14 
B, Cytosine Arabinoside(Ara-C) 
Cytosine arabinoside(Ara-C) is a synthetic 
derivative of naturally occuring arabinonucleosides. 
These are isomers of the ribosyl derivatives but epi- 
meric at the 2* position of the sugar moiety, which were 
first discovered in an unusual sponge in the early 1950's 
(see (24) for further details). First synthesized in 1959, 
it was soon demonstrated to be an effective inhibitor of 
murine leukemia (38). In the late 1960's, extensive cli¬ 
nical tests demonstrated Ara-C to be an effective agent 
in the treatment of acute leukemia in adults (8,37). At 
present, Ara-C is a first-line drug in a variety of com¬ 
bined drug programs for remission induction and maintain- 
ence in acute myeloid leukemia(AML) (87,94). Although it 
is also effective in a percentage of patients with acute 
lymphocytic leukemia(ALL), its value as first-line therapy 
is limited in comparison to the high percent of response 
obtained with other agents (94). However, a good percent 
of responses have been obtained in patients who are re¬ 
sistant to standard therapy(90,94). Ara-C is not effective 
against the chronic or blastic phases of chronic leukemias 
(116). Its role in the treatment of solid tumors has yet 
to be fully defined. A modest response to Ara-C has been 
reported for gastric, ovarian, and pancreatic cancer (1, 
30,31,94), and its effectiveness in combination with other 
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chemotherapeutic agents is being studied. 
The major and dose-limiting side effect produced 
by Ara-C in man is bone-marrow suppression, with resultant 
thrombocytopenia, anemia, and leukopenia with immunosup¬ 
pression. Continuous infusion administration produces a 
greater degree of leukopenia for a longer period than does 
bolus administration (94). The other limiting factor to 
Ara-C treatment is the appearance of a clone of leukemic 
cells that are resistant to the drug. This will be dis¬ 
cussed later. 
The structure and metabolism of Ara-C are shown 
in Figure 2. Studies revealed that the antitumor effect 
of the drug requires uptake and phosphorylation by the 
cells (21,65). Transport of Ara-C corresponds to that 
of deoxycytidine (86), and no barrier to drug uptake has 
been identified in cells resistant to the effects of Ara-C 
(65), but drug resistance in murine leukemia cells, both 
in vitro (21) and in vivo (106), and in normal and leukemic 
human blood cells in vitro(64,65) has been associated with 
a decreased ability to phosphorylate both Ara-C and deoxy¬ 
cytidine. (98) . The enzyme which catalyzes this phosphoryla¬ 
tion has been identified as deoxycytidine kinase(DCK^) 
(36,78). Kinetic studies with the enzyme revealed greater 
affinity for the natural substrate than the drug and, as 
noted in the previous section, significant inhibition by 
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cytidine deoxyribonucleotides (60,78). The production of 
Ara-CMP by DCK^ represents the rate-limiting step in the 
production of Ara-CTP (49), the toxic form of the drug 
(20,65). The ability to form and retain Ara-CTP has been 
correlated with response to Ara-C treatment by Rustum and 
co-workers in both animal(95) and human(97) tumors, and 
and expansion of dCTP pools, with resultant DCK^ inhibition, 
has been related to Ara-C resistance in Chinese hamster 
fibroblasts (32). 
Ara-C is effective only when administered paren- 
terally, and even after rapid intravenous administration 
the drug has an initial plasma half-life of only 3-15 
minutes (52,59) with a second plasma decay phase of 2- 
2% hours (59). The reason for the rapid drop of plasma 
levels is the action of cytidine deaminase(CD), an en¬ 
zyme that is distributed throughout the body, especially 
in liver, kidney, and intestine (16,59), This enzyme con¬ 
verts Ara-C to the inactive form Ara-U (see Figure 2). 
In most species 90-95% of the Ara-C administered appears 
in the urine as Ara-U, humans included (24). Rats, which 
are low in CD, excrete 70% of administered Ara-C unchanged. 
Administration of a synthetic inhibitor of CD, tetrahydro- 
uridine, decreased the rate of Ara-U production in both 
mice (57) and humans (19) and increased Ara-CTP levels in 
leukemias usually resistant to Ara-C (19). Clinical studies 
■* 
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with THU demonstrate significant myelosuppression at 
much lower Ara-C dosage than without the inhibitor (117), 
but have yet to show improvement in response rate. Ara-CMP 
is subject to deamination by DCA2 to dUMP, but the signi¬ 
ficance of this reaction is unknown. 
Steuart and Burke (100) reported elevated CD 
levels in the bone marrows of patients with leukemias re¬ 
sistant to Ara-C relative to CD levels in the marrows of 
patients with leukemias resposive to Ara-C. Tattersall 
et al^.(105) found high levels of CD activity in tandem with 
low levels of DCK^ activity in human AML cells resistant 
to Ara-C. DCA2 activity was unchanged in this study. Ho (57) 
calculated ratios of DCK^sCD in a number of normal and 
neoplastic tissues. He found low ratios in normal peripheral 
white cells and marrow, and in cells from patients with 
CML, while marrow and WBC from patients with AML and CLL 
had high DCK^:CD ratios. A recent study using tetrahydro- 
uridine to inhibit CD has questioned the validity of studies 
relating Ara-C resistance to increased CD activity (52), 
citing the use of lysed cells as a source of overestimating 
CD activity, but failed to settle the matter. Finally, CD 
has been shown to be inhibited by uridine and its analogs, 
most notably DAU (35), which may in part explain the ability 
of DAU to increase cellular Ara-CTP levels (35). 
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A number of agents have been shown to increase 
Ara-C uptake and toxicity. As noted above, cells pretreated 
with thymidine have depleted dCTP pools and exhibit inr- 
creased uptake of CdR from the extracellular space (46). 
Thymidine-depletion of dCTP also results in enhanced 
Ara-C uptake and formation of Ara-CTP (46,86), and in¬ 
creased Ara-C incorporation into DNA. This effect was 
maximized at thymidine concentrations of O.lmM; higher 
concentrations resulted in suboptimal enhancement (46). 
Harkrader et a_l %(50) demonstrated similar effects with 
deoxyadenosine(AdR) and deoxyguanosine(GdR)• Both depleted 
dCTP and dTTP pools to below 50% of control, and AdR de¬ 
pleted CTP and UTP pools as well(GdR was not studied). Both 
enhanced incorporation of Ara-C into DNA, but their effects 
differed in that AdR increased cellular Ara-CTP while GdR- 
treated cells had Ara-CTP levels equal to that of control 
cells. In spite of that, GdR enhanced incorporation of 
Ara-C into DNA to three times normal while AdR increased 
incorporation to twice normal, and GdR displayed greater 
synergy of cytotoxic effect than did AdR (50). 
Methotrexate(MTX) has been shown to synergist ical- 
ly enhance Ara-C cytotoxicity in L1210 cells (13), but only 
when the concentration of MTX used was high enough to re¬ 
sult in free, that is, not bound to dihydrofolate reduc- 
ase, intracellular MTX. Under these conditions, pretreat- 
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raent with MTX decreased intracellular dCTP levels sub¬ 
stantially and resulted in enhanced uptake and phosphory¬ 
lation of Ara-C, presumably via reduction of feedback 
inhibition on DCK^ by dCTP. 
A recent paper by Rauscher and Cadman (89) in¬ 
vestigated the effects of hydroxyurea(HU) pretreatment on 
Ara-C uptake, metabolism, and toxicity, reasoning that 
HU inhibition of ribonucleotide reductase would result in 
depletion of deoxyribonucleotides, including dCTP. They 
demonstrated a time and dose mediated HU enhancement of 
Ara-C uptake and Ara-CTP production for both L1210 murine 
leukemia and HL-60 cells, and remarkable synergy of cyto- 
toxicty in both cell lines, related to dCTP depletion (89). 
Workers in the same lab, working with the L1210 cell line, 
have also recently correlated enhanced Ara-C lethality 
following fluoropyrimidine(5-fluorouracil, S-fluorouridine, 
and 5-fluoro-2'-deoxyuridine, but not 5*-deoxy-5-fluoro- 
uridine) with dCTP depletion, increased Ara-C uptake and 
increased Ara-CTP formation (45). Thus a number of agents 
have been identified which enhance Ara-C toxicity presumably 
by lowering dCTP levels. Studies with DAU and PF will be 
discussed in the following sections. 
Ara-C toxicity is thus a well studied phenomenon, 
but the mechanism by which Ara-CTP kills cells is still a 
matter of controversy. Although early studies suggested 
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that Ara-C might act by inhibiting ribonucleotide re¬ 
ductase (21), or by incorporation into RNA (22), evidence 
soon accumulated that although labelled Ara-C could be 
found in both RNA and DNA (22), the drug acted primarily 
by inhibiting DNA synthesis (24,41,88,94). Thus, its 
action is cell-cycle dependent - it exerts its major toxic 
effect during S phase (41). However, it also tends to 
block the progression of cells from G^ to S, thus to a 
certain extent limiting its own toxicity (41,74). Vad- 
lamudi and Goldin (107) reported enhanced Ara-C toxicity 
in vitro and in vivo after cell-cycle synchronization with 
demecolcine(Colcemid) or vinblastine, timing the Ara-C 
administration to correspond to the entry of the majority 
of the synchronized cells into S phase for maximum lethal 
effect. 
Ara-CTP acts in competition with dCTP, and cells 
treated with Ara-C can, up to a certain point, be rescued 
with CdR (22). The dispute is over whether Ara-C cytotoxicity 
is the result of inhibition of DNA polymerase or incorpora¬ 
tion into DNA and subsequent disturbance of DNA replication. 
Favoring the former hypothesis are kinetic studies with 
viral (74), bacterial (88), and mammalian (39,74) DNA poly¬ 
merases demonstrating interference with dCTP utilization 
without affecting transcription of a poly-dAT template 
(reviewed in (24)), and the discovery of altered DNA poly- 
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merase sensitivity to Ara-C inhibition in bacteria (88) 
and human ALL blast cells (104) resistant to Ara-C. On 
the other hand, a number of studies have demonstrated 
disorders of DNA replication following Ara-C incorpora¬ 
tion (3,33,118) and an early study correlated number of 
chromatid breaks with cell death following Ara-C exposure 
(63). More recently, a number of studies with Ara-C alone 
and in combination with drugs that enhance its lethality 
have correlated cytoxicity convincingly with Ara-C in¬ 
corporation into DNA (45,46,66,89), Therefore, although 
the question of Ara-C toxicity has yet to be resolved, 
the weight of evidence appears to be shifting in favor of 
Ara-C incorporation into DNA, allowing for the development 
of a DNA polymerase that distinguishes between Ara-CTP and 
dCTP as a mode of resistance to the drug. 
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C. 3-Deazauridine(DAU) 
3-Deazauridine(DAU) is a uridine analog in which 
the of the pyrimidine ring is replaced by carbon (see 
Figure 2)f first synthesized by Robins and Currie (92) in 
1968. It was shown to inhibit the growth of E.Coli and 
L1210 cells in vitro (93) and to increase the lifespan 
of L1210 tumor-bearing mice (96). Uridine kinase phosphory- 
lates the drug to DAU-MP (9), from which DAU-TP, the active 
form of the drug (76), is formed. The drug inhibits both 
DNA and RNA synthesis without significantly affecting pro¬ 
tein synthesis (9). McPartland §t a_l .demonstrated inhibition 
of the enzyme responsible for the deamination of UTP to 
CTP, cytidine triphosphate synthetase(CTS), by DAU-TP (76), 
and this was supported by findings that DAU toxicity could 
best be reversed by cytidine and to a lesser extent by de- 
oxycytidine or uridine (9,76). Reversal of toxicity by uri¬ 
dine agrees with findings that DAU inhibition of CTS is com¬ 
petitive with respect to UTP (76). Deoxyuridine and thymi¬ 
dine did not reverse DAU inhibition of nucleic acid synthe¬ 
sis. Recently, DAU and DAU-MP have been shown to inhibit 
CD and DCA^, respectively (15,35), although the importance 
of this in the intact organism is uncertain. On administration 
of the drug to humans relatively rapid excretion of un¬ 
changed drug in the urine is noted, with an initial plasma 
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half-life of 1-1% hours (27), and a terminal half-life 
from 4 to 10 hours (27,28) after rapid administration. 
The drug has a relatively large volume of distribution 
(18.8 liter/kg), thus continuous infusion led to a 
higher terminal half-life, averaging 21.3 hours in a 
study by Benvenuto et_ al_.(4). Dose-limiting toxicities 
include nausea, vomitting, and oral stomatitis; marrow 
suppression is rare (27). Clinical trials with DAU in 
acute leukemia (120) and solid tumors (101) have been 
disappointing, leading to suggestions that DAU may prove 
most useful in combination with other agents. 
Early studies with DAU by Brockman eit al. (9) 
and Rustum et al.(96) demonstrated that L1210 cells re¬ 
sistant to the effects of Ara-C were more susceptible to 
DAU than L1210 cells susceptible to Ara-C. Evidence for 
three possible mechanisms for this effect appeared. First, 
L1210 cells resistant to Ara-C(L1210/A) had lower baseline 
dCTP levels than L1210 cells sensitive to Ara-C(L1210/0) 
(9,96), likely due to deficient DCK^ activity, thus making 
them more dependent on the CTS pathway for dCTP. Second, 
L1210/A cells formed more DAU-TP than L1210/0 cells (96). 
Finally, despite equal UTP pools, CTP production in L1210/A 
cells from labelled UTP was lower than CTP production in 
L1210/0 cells (96). Thus the evidence suggests DAU in com¬ 
bination with Ara-C would help guard against the emergence 
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of an Ara-C resistant clone. In addition, CTP depletion 
following DAU exposure suggested its use to enhance Ara-C 
action in Ara-C sensitive cells as well (77). 
Studies combining DAU and Ara-C have noted marked 
increases in Ara-C uptake (86), formation of Ara-C phos¬ 
phates, especially Ara-CTP (77), and doubled incorporation 
of Ara-C into DNA (86)t the likely source of the poten¬ 
tiated anti-proliferative effect noted in some (77) but not 
all (62) cell lines. DAU inhibition of cytidine deaminase 
is another possible source of enhancement (15,35). Lauzon 
et a_l.'{68) noted arrest at the early S phase of cells ex¬ 
posed to 10/#M DAU for 16 hrs, with enhanced Ara-C toxicity 
when exposed after transfer to medium containing no DAU. 
Unfortunately, enhanced toxicity towards tumor cells in 
culture may also signal more severe toxic side-effects in 
the whole animal, and Paterson et a_l.(84) noted drug-se¬ 
quence dependent severe small bowel mucosal injury and 
death in mice treated with relatively small doses of DAU 
then Ara-C. 
In a single clinical study on the effects of 
DAU and Ara-C for patients with relapsed acute leukemia 
(2), Barlogie e£ a_l. noted lower DAU-TP levels for either 
drug sequence than for DAU alone. Moreover, DAU-caused 
CTP depletion was not consistently associated with elevated 
Ara-CTP levels* and little clinical response was obtained, 
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though it should be noted that this was a group of 
patients who had already been exposed to Ara-C. 
In combination with 5-azacytidine, a cytidine 
analog incorporated into RNA and presumed to exert its 
lethal effect by inhibiting protein synthesis (reviewed 
in (44)), DAU exerts a synergistic lethal effect, likely 
via depletion of CTP, the feedback inhibitor of UK, the 
enzyme required to activate 5-azacytidine. In combination 
with D-galactosamine, which depletes hepatic UTP, DAU- 
mediated depletion of CTP in rat hepatomas was very pro¬ 
nounced (up to 86%) (71), and in hepatomas this combina¬ 
tion was strongly synergistic, as opposed to only additive 
effects in non-hepatic cell lines (62). 
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D, Pyrazofurin(PF) 
Pyrazofurin(PF) is a C-nucleoside antibiotic 
(see Figure 2) isolated from the fermentation broth of 
a strain of Streptomyces candidus (103) demonstrated to 
inhibit growth of many, though far from all, tumors in 
vitro (11,47,103) and to prolong survival in rats inocu¬ 
lated with sensitive tumors (103). Most encouraging were 
the responses of solid tumors usually resistant to chemo¬ 
therapy. Drug toxicity results from the formation of PF- 
MP from the action of adenosine kinase(AK) on PF (see 
Figure 2) (34); di- and triphosphate derivatives are formed 
but are inactive (34). This is corroborated by inhibition 
of PF phosphorylation by adenosine, but not other nucleo¬ 
sides (34), and the development of drug-resistant sublines 
demonstrated to be freely permeable to PF but lacking AK 
activity (34). 
Dix et al^. (34) demonstrated rapid competitive 
inhibition of orotidylate decarboxylase(OTD), the enzyme 
responsible for conversion of OMP to UMP (see Figure 1), 
as suggested by earlier studies which noted blockade of 
orotate metabolism (11) and reversal of PF toxicity in 
the presence of uridine or cytidine, but not purine nu¬ 
cleosides (11,83,85). Resistance in some cases may be due 
to enhanced ability to re-utilize uridine (11), and has 
been associated with elevated OTD activity (34,102). 
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The major toxic effect of PF exposure is inhibition of 
DNA synthesis, as indicated by profound suppression of 
deoxyadenosine incorporation in treated cells, and re¬ 
versal of PF toxicity with deoxycytidine and thymidine 
in experiments by Plagemann and Behrens (85). PF en¬ 
hances uridine uptake and eventual incorporation into 
DNA in cell lines capable of sufficient salvage (11,85). 
OTD activity, as well as pyrimidine nucleotide 
(ribo- and deoxyribonucleotides) levels, were elevated 
in a variety of tumors studied by Weber et al.(114). 
PF severely depletes animal tumor cells of these nu¬ 
cleotides (10,113,114) in culture. Grown in ascitic fluid 
UTP levels remained low in both sensitive and resistant 
cell lines, but CTP levels, initially depressed in both, 
returned to normal levels within 10 hours in a resistant 
cell line (11). Evidence for PF inhibition of purine syn¬ 
thesis, except via competitive inhibition of adenosine re 
utilization (85), is scant, though Worzalla and Sweeney 
(119) have reported inhibition of purine biosynthesis and 
PF-treated cells have exhibited ATP and GTP depletion as 
well as UTP and CTP depletion (10,113). 
Cell cycle specificity of PF action has been 
studied by Hill and Whelan (55) and Olah et al^. (83). The 
former pair related cell kill more to duration of expo¬ 
sure than concentration, finding cell kill predominantly 
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occurring in at low drug concentrations, but S phase 
toxicity at higher concentrations, with accumulation of 
cells in S phase or at the G^/S boundary. The latter group 
agreed with the dominance of S phase killing at high con¬ 
centrations (300, but found equal toxicity to early G^ 
and early S phase cells for lower (10-25j»M) concentrations. 
The importance of S phase killing is underscored by the 
limitation of PF toxicity to cells in logarithmic growth- 
plateau phase cells were unaffected (83). 
Studies of PF in combination with Ara-C have 
suprising results. Greater than additive effects inhibiting 
cell growth and clone formation have been reported (11,55), 
but the mechanism of this synergy is unclear. While CTP 
(and presumably dCTP) depletion would remove feedback in¬ 
hibition of DCK^, leading, in theory, to increased Ara-C 
uptake and phosphorylation, PF pretreatment has not been 
found to increase Ara-C uptake or acid-soluble Ara-CTP 
(11,86). However, simultaneous PF and Ara-C markedly stimu¬ 
lated Ara-C uptake (86), and Ara-C incorporation into 
DNA was 15X control over the first 60 minutes (86). 
PF markedly enhanced 5-azacytidine toxicity 
against murine leukemia cells in vitro (12) by increasing 
5-azacytidine 5'-triphosphate formation, presumably by 
reducing UTP/CTP inhibition of uridine kinase. PF and D- 
galactosamine in combination synergistically depressed 
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UTP and CTP pools and exhibited more than additive cyto¬ 
toxic effect (114). 
.In response to data from in vitro and animal 
studies demonstrating significant antitumor activity with 
PF alone (11) or in combination with 5-azacytidine (12,18), 
extensive clinical trials were undertaken. After some initial 
encouraging results (81), studies have indicated no sig¬ 
nificant antitumor effect of PF alone in a large variety 
of tumors (14,17,26,30,43,67,109,110) or improvement of 
5-azacytidine effect in acute leukemia (73,108). Significant 
toxicity in the form of dermatitis and stomatitis was uni¬ 
versally noted, and myelosuppression was noted after prolonged 
treatment, though decreasing dose frequency to weekly 
seemed to attenuate this side effect (30). Unless PF can be 
shown to enhance the antitumor effect of other agents, its 
usefulness as a chemotherapeutic agent will likely be 
limited 
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II. MATERIALS AND METHODS 
A. Materials 
Ara-C, Ara-CTP, ATP, CTP, GTP, and UTP were 
purchased from Sigma Chemical Company(St. Louis, MO). 
PF was a gift from Ely Lilly & Company(Indianapolis, 
Ind.). DAU was obtained from the Drug Development Branch, 
3 
National Cancer Institute, Bethesda, Md. 5,6- H-Ara-C 
(18 Ci/mmol) was purchased from Moravek Biochemicals, 
Inc.(City of Industry, CA). These were stored as powders 
in a dessicator tray at -5°C. Solutions of Ara-C, PF, 
and DAU were prepared by adding the drug to sterile water 
—4 3 
and stored at -5°C between experiments. 10 M H-Ara-C 
was prepared by adding 0.1 ml labelled Ara-C to 1.0 ml 
1.044 X 10”4M 'cold' Ara-C. Ara-CTP, ATP, CTP, GTP, and 
UTP standards for the HPLC were prepared using carefully 
weighed ammounts of the pure compounds in 5.0 ml 75% 0.5M 
NH4H2P04(pH 4.85):25% 5mM NH^PO^pH 2.8), the buffer 
mixture at which the nucleoside triphosphates were eluted 
from the column. 
Liquiscint was purchased from National Diag- 
nostics(Somerville, NJ). All media referred to in the 
next section were purchased from Grand Island Biologicals 
Company(Gibco; Grand Island, NY). 
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B. Cells 
Murine leukemia L1210 cells were maintained 
as a stationary suspension culture in Fischer's medium 
with 10% horse serum added at 37°C in a 5% CC>2 atmos¬ 
phere and transferred twice weekly. Cultures done every 
two months for mycoplasma contamination were negative. 
A 
Cells were inoculated at 5 X 10 cells/ml and used in 
logarithmic growth phase, between 1 and 1.5 X lO^cells/ml. 
HL-60 is a human promyelocyte leukemia cell 
line derived from the peripheral blood leukocytes of a 
patient with acute promyelocytic leukemia. As described 
by Gallagher et al (40), the cell line has been identi¬ 
fied as a neutrophilic promyelocyte with prominent nu¬ 
clear/cytoplasmic asynchrony. HL-60 cells were passed 
twice weekly in RPMI 1640 medium supplemented with 1% 
lOmM Sodium Pyruvate, 1% lOOmM Nonessential Amino Acids 
(NEAA), and 10% heat-inactivated, dialyzed fetal bovine 
serum(DFBS) and maintained at 37°C in a 5% CO^ atmos¬ 
phere. 
Double-strength McCoy's medium(2X McCoys) used 
for HL-60 cloning experiments was prepared by dissolving 
a 1 liter package of powdered Gibco McCoy's 5a Medium in 
450 ml sterile water and adding 
2.2 grams Sodium Bicarbonate 
6.0 ml Gibco NaHCCU solution(pH 7.57) 
10.0 ml Gibco lOmM Sodium Pyruvate 
8.0 ml Gibco MEM Amino Acids 
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4.0 ml Gibco NEAA 
4.0 ml Gibco MEM Vitamins 
2.5 ml Gibco Penicillin/Streptomycin 
15.0 ml Gln-Ser-Asn solution, 
the last of which was prepared by adding 160 mg L-as- 
parginine and 84 mg L-serine to 100 ml sterile water, to 
which is then added 40 ml Gibco L-glutamine solution. 
Cells were counted in 0.9 M NaCl on a Coulter 
Model ZBI Counter (Hialeah, FL). 
C. Soft Agar Cloning Assay 
The soft agar cloning assay used to determine 
survival of L1210 cells has been described by Cadman et 
al .(12) as a modification of a technique initially re¬ 
ported by Chu and Fischer (22). Log phase L1210 cells at 
1 - 1.5 X 10^cells/ml were used for the cloning studies. 
10 ml of cells were exposed to DAU, PF, or Ara-C as per 
the experimental design. For sequential drug exposures, 
at the end of the first drug exposure the cell suspension 
was centrifuged at 1000 rpm for 8 minutes. The drug-con¬ 
taining supernatant was discarded and the cell pellet 
resuspended in fresh medium. This process was repeated 
to remove any extracellular drug before the addition of 
the second drug. An identical washing sequence was used 
at the end of the drug exposures. 
A 1:10 dilution of the resuspended cells was 
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counted, and a final cell suspension with a concentration 
of 50 cells/ral was achieved with further dilution. 2.0 ml 
of this suspension was added to 3.0 ml of a 0.2% Difco 
Bacto-Agar - Fischer’s medium with 15% horse serum mix¬ 
ture in 10 ml culture tubes and gently rocked to mix the 
contents without introducing air bubbles. The tube was 
then set upright in ice for 3 minutes to hasten setting 
of the soft agar, then incubated at 37°C in a 5% CO^ 
atmosphere. 
The consistency of the soft agar allowed con¬ 
tinued cell growth and division without cell settling or 
random motion. Within 10 days, cells that had remained 
viable and retained the ability to divide after the drug 
exposure(s) had produced single cell colonies (clones). 
The effect of drug treatment can therefore be expressed 
as the percentage of clones formed relative to untreated 
cells, which had a cloning efficiency of 70%. All experi¬ 
ments were done in quadruplicate, and values represent 
mean values. 
D. Bilayer Cloning Assay 
The method used for determining the effect of 
cytotoxic drug exposures on the viability of HL-60 cells 
was a modification of the bilayer cloning assay described 
by Hamburger ££.al_.(48). The bilayer consists of a basal 
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nutrient layer onto which the layer containing the cells 
being studied is applied. The consistency of the cell 
layer does not allow cell settling or random cell motion, 
but does permit continued growth. Cells that remain vi¬ 
able after drug exposure, as defined by the capability 
to continue to divide, form individual cell colonies 
(clones) that are visible at 40 X on a phase-contrast 
microscope within 15 days. 
The nutrient layer consists of a 2:1:2 mixture 
of 2X McCoys:DFBS:1.2% Difco Bact-Agar, the last of which 
had been melted and allowed to cool to approximately 40PC 
before adding it to the other ingredients. Under sterile 
conditions 1.0 ml of this mixture was dispensed into the 
base of four of six 35mm diameter, 14mm deep wells, being 
careful to avoid introducing bubbles that would hinder 
counting. The other two wells were filled with 2 ml ster¬ 
ile water to prevent the agar from drying out. The bottom 
layer was allowed to harden at least 2 hours at 37°C. 
Log phase HL-60 cells at 1.5 - 2 X 10^cells/ml 
were counted, then diluted to 50,000 cells/ml.with fresh 
medium. 2.0 ml of this cell suspension were exposed to 
DAU, PF, or Ara-C as per the experimental design. For 
sequential drug exposures, at the end of the first drug 
exposure the cell suspension was centrifuged at 1200 rpm 
for 10 minutes, the supernatant poured off, and the cells 
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resuspended in 2.0 ml fresh medium before the second drug 
was added. 
At the end of the drug exposures the cell sus¬ 
pension was centrifuged at 1200 rpm for 10 minutes, the 
supernatant poured off, the cell pellet washed in fresh 
medium and recentrifuged as before to remove extracellu¬ 
lar drug. The cell pellet was resuspended in 2.5 ml IX 
McCoys, of which 1.0 ml was used to establish an accurate 
cell count. A final concentration of 2500 cells/ml(5000 
for those drug treatments presumed highly toxic) was 
achieved by adding to 3.0 ml IX McCoys an ammount of the 
cell suspension determined by the formula 
Ammount(in ml) * 7500/CX-2500) for 2500 cells/ml 
15000/(X—5000) for 5000 cells/ml 
where X equals the cell count per ml of the initial solu¬ 
tion. 
The diluted cell suspension was mixed well, 
then 0.5 ml was added to a mixture of 0.75 ml 2X McCoys 
and 0.5 ml DFBS. To this mixture was added 0.75 ml 1.0% 
Bacto-Agar that had been melted then allowed to cool to 
approximately 40°C. Before this mixture began to gel, 1.0 
ml was dispensed into each of two wells onto the now-solid 
basal nutrient layer. Thus 500(or 1000) cells were seeded 
per well, and incubated at 37 C with 5% C02« 
Clones were counted at 15 days using a phase- 
contrast microscope to scan the entire well at 40 X. 
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Growing clones were easily distinguished from debris or 
small cell clumps. The effect of the drug treatments can 
be expressed as the percentage of clones formed after 
drug treatment versus clones formed by untreated cells. 
The cloning efficiency of control cells was 67%. 
E. Ara-C Uptake 
The procedure used to quantitate Ara-C uptake 
was essentially as described by Grant e£ al „(46). 50 ml 
of logarithmically growing cells, between 1.5 and 2 X 
lO^cells/ml, were exposed to DAU and/or PF as per the 
experimental design, then centrifuged at 1200 rpm for 
10 minutes. The drug containing medium was removed and 
the cell pellet was resuspended in 2.1 ml fresh medium. 
After 0.1 ml was removed for a determination of the cell 
concentration, the 2.0 ml solution (at 4 - 7 X 10^cells/ml) 
was placed in a 10 ml stoppered flask and allowed to equi- 
3 librate in a 37°C shaker water bath. H-Ara-C was added 
(0.06 ml of a 10*”^M solution) to achieve a final concen¬ 
tration of 3/jiM with a specific activity of 1718 mCi/mmol. 
At 5, 10, 15, 20, 30, and 60 minutes 0.1 ml 
aliquots of the agitated cell suspension were added to 
0.5 ml plastic microfuge tubes which had previously been 
layered with 0.04 ml 5% perchloric acid and 0.1 ml of an 
84:16 mineral oil:silicone oil mixture. The aliquots were 
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mediuorv 
oil ^ 
immediately centrifuged at 10,000 rpm for 
15 seconds. The oil layer permitted only 
the cells, not the medium, to pass to the 
perchlorate-containing tip (see diagram 
at right), where the cells lysed. The tubes 
were frozen in a 70% ethanol/dry ice bath and cut in the 
oil layer, which, according to Grant ^t ji!.(46), retains 
no radioactive material, to separate intracellular from 
extracellular label. Each fraction was immersed in 4 ml 
Liquiscint in a 7 ml counting vial. After vigorous agi¬ 
tation to dislodge the cell pellet and distribute the 
radiolabel, each fraction was counted for three minutes 
by a Packard Model 3255 Tri—Carb Liquid Scintillation 
Spectrometer, 
Two samples were taken for each time point and 
the Ara-C content of the cell fractions was determined 
using the following equation: 
3 H-Ara-C 
ml 
ml CPM(Cell Fx) 
=*>>■>* >”6> sss 
Ara-C uptake 
10 cells 
Values from repeated experiments were averaged and used 
to generate lines whose slopes can be expressed as 
3 6 H-Ara-C uptake/10 cells perminute. 
F, Ribonucleotide Triphosphate and Ara-CTP Analysis 
Ribonucleotide triphosphate levels were deter— 
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rained using a modification of procedures described by 
Harkrader e£ a_l.(50) and Lui et al_%(71). After drug ex¬ 
posures, cell concentration was measured, then approxi- 
7 
mately 10 cells were harvested by centrifugation at 1500 
rpm for 3 minutes. The supernatant was meticulously removed 
to avoid contamination of the cell extracts by substances 
in the medium; this included wiping down the walls of the 
centrifuge tube with a paper towel. The cell pellet was 
extracted in 0.4 ml of ice-cold 0.7 N perchloric acid, 
vigorously agitated, then centrifuged at 1500 rpm to re¬ 
move precipitated protein and nucleic acids. To the super¬ 
natant was added potassium bicarbonate until the pH was >7, 
followed by centrifugation to remove precipitated potassium 
perchlorate. 0.3 ml of this supernatant was added to 0.06 
ml 1 W HC1, bringing the pH approximately to 5. 
Aliquots of 0.25 ml were analyzed using an Altex 
Model 334 High Pressure Liquid Chromatograph. A 4.0 mm X 
25 cm column of Partisil-10 SAX(Whatman, Clifton, NJ) was 
eluted with a starting buffer of 5mM ammonium phosphate, 
pH 2.8. At 4 minutes 0.5M ammonium phosphate, pH 4.85, 
was added to the starting buffer. Figure 3 illustrates 
the relation between column time and percent high pH 
buffer. Total flow rate was 2.0 ral/min. and column pres¬ 
sure was approximately 1500 psi. Peaks were detected by 
ultraviolet absorbance at 280 nra, the longer wavelength 
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substituted for the standard 254 nm to enhance CTP de¬ 
tection, and displayed as a continuous function of ab¬ 
sorbance vs. time (see Figure 14 for an example). 
Peaks were translated into NTP levels using 
the cut-and-weigh procedure. To correct for baseline 
drift due to the buffer system's intrinsic increased 
absorbance as the percent of the more concen 
trated high pH buffer increased, the baselin 
was interpolated under the closely-spaced 
peaks in the triphosphate region. The dotted 
line in the diagram at right is an example 
of this. Overlap areas were divided by drop¬ 
ping a perpendicular from the nadir between 
the peaks(the solid line in the diagram). 
The chromatograms were copied onto xerox paper of mea- 
-2 2 
sured average density (7.133 X 10 mg/mm ) and care¬ 
fully cut out and weighed. Location of the NTP peaks 
and the NTP concentrations were determined by comparison 
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with chromatograms produced by known ammounts of pure 
compounds. Division of the number generated by this method 
by the cell count determined to be in the 0.25 ml aliquot 
0 
applied to the column yielded the result in picomoles/10 
cells. 
A pure sample of Ara-CTP yielded a single peak 
in the NTP region of the chromatogram (see also Figure 12 )• 
3 
H-Ara-CTP was quantitated by collecting the eluent for 
the NTP region (between 24 and 34 minutes column time) 
as 1 minute fractions. These fractions were combined with 
3 ml Liquiscint in a 7 ml counting vial and the decay of 
the tritium label was averaged over three minutes by the 
Packard Liquid Scintillation Spectrometer. Investigation 
revealed, however, that the gel formed by the combination 
of the aqueous buffer solution with the Liquiscint resulted 
in a 44% counting efficiency relative to the same ammount 
of radioactive material in the same volume of pure Liqui¬ 
scint. Consequentially, values obtained by this method 
were multiplied by 2.29 to relate them to values obtained 
in the drug uptake studies. 
G. Statistical Analysis 
Synergy of cytotoxic drug combinations was deter¬ 
mined simply by dividing the observed clone survival by 
the expected clone survival, where the expected survival 
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is the product of observed survival rates for the indi¬ 
vidual drugs. For triple drug exposures a second ’expect¬ 
ed* value was obtained by multiplying the observed survi¬ 
val rate for the first drug alone by the observed survi¬ 
val rate for the combination of the other two, when that 
combination had been tested. If Obs/Exp <. 1.0, the drug 
combination was considered to have synergistic cytotoxic 
effects. When Obs/Exp >1.0, the drug combination was con¬ 
sidered antagonistic. When Obs/Exp as 1.0, the effects of 
the drugs were considered additive. 
For Ara-C uptake studies, lines of best fit 
were determined using the method of least squares. The 
correlation coefficient r was calculated as 
r . I(x-x)(y-y) *2 . (r)2 
Z(x-x)E(y-y) 
and the significance of r was determined using the 
Student-t test with 
tn_2 = r(n-2)5s/(l-r2)’5 
For the experiments summarized in Figure 10 and Table 4 
2 
p<0.001 in all cases. R values were calculated for the 
lines obtained from mean uptake values and one-tailed t 
tests were performed to determine significant differences 
3 
in H-Ara-C uptake. 
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III, RESULTS 
A, Cloning Experiments 
1. L1210 
The results of the cloning experiments with L1210 
are presented in Table 2. By themselves, DAU and Ara-C ex¬ 
hibited substantial toxicity towards L1210 cells in culture. 
The toxic effect of PF at the concentrations/duration studied 
was limited. Greater than additive effect on clone survival 
was noted for both DAU and PF when combined with Ara-C. In 
both cases the synergy was greater when Ara-C was preceded 
by the CTP-depleting drug than when Ara-C exposure was first, 
with a more noted difference for DAU than PF. Triple drug 
exposures resulted in remarkable synergy when DAU and PF, 
in either order, preceded Ara-C. Ara-C followed by PF and 
DAU exhibited synergy of the same order as the double drug 
exposures. 
2. HL—60 
The results of the cloning experiments with HL-60 
are presented in Table 3. By itself, DAU exposure, up to 
10/»M for 3 hours, had no effect on the ability of HL-60 
cells to produce a clone. PF exhibited modest toxicity, 
and Ara-C exhibited a linear log-dose X response relation- 
. 2 
ship between concentrations of 0.1 to 20/*M (* «0.96, slope 
= -23.35% clone survival/log^concentration). Pretreatment 
with 3j*M DAU did not enhance Ara-C toxicity, but 5/jlM DAU 
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Table 2 : Results of L1210 Cloning Experiments 
Treatment* 
% Clone 
Observed 
Survival(Ccntrol=100.0) 
Expected ~ 
(Additive Obs/Exja 
PF 2pM 100.0 ____ — 
PF 5pM(l hr) 88.9 — — ——-* 
PF 5p N 79.4 — 
DAU IpH 83.0 — 
DAU 2v M 70.5 ——- -- 
DAU 5pM 46.7 — — — 
Ara-C lpM 96.1 — 
Ara-C 2p M 62.1 — — 
Ara—C 5pM 46.0 — —- 
Ara—C 7 • 5p M 33.4 — -—- 
Ara-C 10pM 22.5 — 
PF 2u H» Ara-C 2 pH 25.4 62.1 .409 
PF 2pM, Ara-C 5 pM 22.2 46.0 .483 
PF 5pM, Ara-C 2 uM 26.2 49.3 .531 
PF 5pM, Ara-C 5 PM 16.7 36.5 .458 
Ara-C 2pM, PF 2pH 34.1 62.1 .549 
Ara-C 2pM, PF 5 pH 29.4 49.3 .596 
DAU lyM, Ara-CTipM 31.0 79.8 .388 
DAU lyM, Ara-C 3pM 
DAU lpM, Ara-C SvM 
16.3 
10.9 38.2 1205 
DAU 2pM, Ara-C lp M 23.3 67.8 .344 
DAU 2UK, Ara-C 3p M 
DAU 2pM, Ara-C 5pM 
12.4 
11.6 32.4 .358 
Ara-C lpM, DAU 5pM 31.0 44.9 .690 
Ara-C 5pH, DAU 2p M 23.3 32.4 .719 
Ara-C 5p Mf DAU 5p M 16.3 21.5 i 758 
PF 2, DAU 2, Ara-C 2 0.4 43.8 .009 
FF 2, DAU 2, Ara-C 5 0.8 32.4(11.6) .025(.069) 
PF 5, DAU 2, Ara-C 2 2.0 34.8 .057 
PF 5, DAU 2t Ara—C 5 2.0 25.7( 9.2) .078(.217) 
DAU 2, PF 5, Ara-C 2 1.2 34.8(18.5) .034(.065) 
Ara-C 2, PF 5, DAU 2 13.5 34.8 .385 
Ara-C 5, PF 5, DAU 2 9.9 25.7 .305 
•—PPtDAU treatments lasted 3 hrs, Ara-C treatments 1 hour. 
A 
-Determined t>y multiplying single drug values. Values in 
parentheses were determined by multiplying the value for 
the first drug alone by the value obtained for the com¬ 
bination of the second and the third drugs. 
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Table 3; Results of HL-60 Cloning Experiments 
% Clone Survival(Control=100.0) 
Expected 
Treatment Observed (Additive) Obs/Exp 
DAU 3yM 100.0 
DAU 5yM 100.0 — ——- 
DAU 10yM 100.0 — — 
PF 3y M 100.0 
PF 5y M 92.5 ——— ———— 
PF lOy M 83.1 — -- 
Ara-C O.lyM 100.0 „ !— |.„ .. 
Ara-C 0.3y M 92.0 — ——— — 
Ara-C ly M 85.0 —— 
Ara-C 3y M 73.8 —- — — — 
Ara-C 5y M 66.4 —- -- -- 
Ara-C lOy M 52.5 —— —— 
Ara-C 20y M 47.5 — -- 
DAU 3yM, Ara-C 89.7 85.0 1.06 
DAU 3yM, Ara-C 3 ;M 84.1 73.8 1.14 
DAU 3y M, Ara-C 5 yM 77.3 66.4 1.16 
DAU 5yM, Ara-C 3yM 56.4 73.8 0.76 
DAU 5yM, Ara-C 5yM 29.3 66.4 0.44 
Ara-C 3yM, DAU 5yM 61.4 73.8 0.83 
PF 3yM, Ara-C lyM 100.0 85.0 1.18 
PF 3yM , Ara-C 3yM 73.6 73.8 1.00 
PF 3yM, Ara-C 5yM 70.2 66.4 1.06 
PF 5yM, Ara-C 3yM 59.5 68.3 0.87 
PF 5yM, Ara-C 5yM 54.2 61.4 0.88 
Ara-C 3yM, PF 5yM 43.2 68.3 0.63 
DAU 5yM, PF 5yM 91.7 92,5 0.99 
PF 5yM, DAU 5yM 81.2 92.5 0.88 
D 2 yM, P 2yM, A 1 jJM 68.2 85.0 0.80 
D 2 yM, P 2yM, A 3 yM 40.1 73.8 0.54 
D 2 yM, P 5yM, A 1 yM 63.2 78.6 0.80 
D 2yM, P 5yM, A 3 yM 56.9 68.3(59 .5)0.83(0.96) 
D 5 yM, P 2y M, A 1 yM 45.4 85.0 0.53 
D 5 yM, P 2yM, A 3yM 37.4 73.8 0.51 
D 5 yM, P 5y M, A lyM 62.9 78.6 0.80 
D 5 yM, P 5y M, A 3yM 34.1 68.3(59 .5)0.50(0.57) 

46 
Table 3: Results of HL-60 Cloning Experiments 
% Clone Survival(Control=100.0) 
Expected 
Treatment Observed (Additive) Obs/Exp 
P 2 vM, D 5y M, A lyM 21.1 85.0 0.25 
P 2yM, D 5y M, A 3yM 19.6 73.8(56.4) 0.27(0.35) 
P 5yM, D 5y M, A 3yM 18.4 68.3(52.2) 0.27(0.35) 
P 5yM + D » 5yM^ A > 3yM 40.0 66.4 
o
 
o
 
• simultaneous exposure to DAU and PF 
A 3u^, P 5y M, D 5yM 41.5 68.3(59.9) 0.61(0.69) 
A 3iM, D 5yM, P 5yM 48.4 68.3(67.7) 0.71(0.71) 
D 5yM, A 3yM, P 5yM 48.3 68.3(43.2) 0.71(1.12) 
P 5 yM, A 3yM, D 5yM 17.0 68.3(56.8) 0.25(0.30) 
PF and DAU treatments lasted 3 hours, Ara—C treatments 1 hr. 
was associated with observed/expected clone survival less 
than 1. Experiments with the sequence reversed had similar 
results. PF pretreatment (2 or for 3 hours) of Ara-C 
exposed cells resulted in additive effects on clone survival, 
with the reverse sequence suprisingly more effective at re¬ 
ducing clone survival. PF did not appreciably enhance DAU 
toxicity, though PF preceding DAU was marginally more toxic 
than PF following DAU. 
DAU followed by PF prior to Ara-C exposure resulted 
in greater than additive cytotoxicity, cutting survival in 
half, vs. expected values, for 3/*M Ara-C. The most toxic re¬ 
gimen was PF followed by DAU then Ara-C, with which clone 
survival was cut to 20% of controls, about one-fourth of 
expected survival. A similar result was noted when PF and 
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Ara-C were followed by DAU, but not when DAU and Ara-C 
precede PF. Treating with Ara-C first, followed with DAU 
and PF in either order, was less effective than when Ara-C 
was the final drug to which the cells were exposed. PF 
and DAU simultaneous exposure was as effective as DAU fol¬ 
lowed by PF in sensitizing the cells to Ara-C, but not as 
effective as the PF followed by DAU sequence. 
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B. Ara-C Uptake 
Presenting the results of the Ara-C uptake 
studies requires two brief explanations. First, as dis¬ 
cussed above, the transport of nucleosides, including 
Ara-C, into cells is a very raDid, first-order process 
(6,86), but the uptake of a nucleoside is deoendent upon 
its rate of phosphorylation (86) and, in the case of Ara-C, 
its conversion to other forms (Ara-U, Ara-UMP) which es¬ 
tablish their own concentration gradients across the cell 
membrane. In these experiments, beyond approximately 20 
minutes exposure to Ara-C, the rate of uptake declined, 
and total uptake began to level off. For statistical pur¬ 
poses, results were plotted as total uptake vs. time and 
lines, whose slopes are expressed in uptake per minute 
were drawn using values from the first four time-points 
(5, 10, 15, and 20 minutes) only. Figures 6 and 7 contrast 
this method of extrapolation with actual uptake values, 
and the 60 minute values are identified on all figures. 
Justification for treating the data in this fashion comes 
from the observation.that in the intact organism Ara-C is 
rapidly cleared and metabolized (52,59), thus the initial 
rate of uptake becomes the most vital determinant of total 
uptake. 
Second, statistical comparisons between drug re¬ 
gimes were performed on rates of Ara-C uptake instead of 
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absolute values of total uptake* Though in most cases 
significant differences in rate were accompanied by 
significant differences in total uptake (by 15 minutes 
exposure), rates of uptake varied less than total uptake 
in repeated experiments - compare Figure 10 with Table 4. 
1. L1210 
In a single experiment performed with L1210 
cells, pretreatment with DAU enhanced intracellular 
Ara-C accumulation (Figure 4), increasing the rate of 
Figure 4: 
Effect of 
Concentration of 
DAU ^Pretreatmen t 
on M-Ara-C (5/iM) 
Uptake in 
L1210 Cells 
extrapolated 
from 5 and 20 minute 
timepoints 
-- actual uptake 
values 
•m*rate of ^H-Ara-C 
Uptake as 
lO’^moles/lO^cells 
minute 
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M ry fT 
treated cells to 4.40, 5.83, and 7.23 X 10 moles/10 cells 
minute for cells pretreated for 3 hours with lyM, 2yM, 
and 5yM, respectively. 
2. HL-60 
Figure 5 demonstrates that increasing the initial 
3 
concentration of H-Ara-C from lyM to 3yM to 5yM can sig- 
nificantly (p<.05) increase the rate of H-Ara-C uptake 
by HL-60 cells. Pretreating cells for 3 hours with con- 
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centrations of PF ranging from 1 to 10 M had no significant 
3 
effect on H-Ara-C uptake (Figure 6) as previously noted 
by Cadman et al.(ll) and others (86). 
Figure 6: Effect of-Concentration of PF Pretreatment on 
2 ^H-Ara-C Uptake 6 
•m=rate of H-Ara-C uptake as 10** moles/10 cells 
minute 
In contrast, DAU pretreatment markedly increased 
uptake of the labelled drug. As illustrated in Figure 7, 
3 
the baseline uptake of H-Ara-C, expressed as picomoles 
per lO^cells per minute, of 2.3 exhibited a modest increase 
in response to 3-hour pretreatment with l>*M(rate«2.5) or 
3>*M(2.6) DAU. Pretreatment with 5j*M DAU resulted in sig¬ 
nificantly higher Ara-C uptake(rate=3.4, p<0.01) than control. 
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Pretreatment with 10y*M DAU was no more effective at in- 
3 
creasing H-Ara-C uptake than 5j*M. 
Figure 7: Effect of-Concentration of DAU Pretreatment on 
- ^H-Ara-C Uptake * ? 6 
•m=rate of H-Ara-C Uptake as 10*“ moles/10 cells 
@ p<0.01 minute 
# p<0.05 
Figures 8 and 9 illustrate the effect of fol¬ 
lowing DAU pretreatment with PF before exposing the cells 
3 
to H-Ara-C( 3;aM) . in Figure 8, increasing concentrations 
3 
of PF result in increases in the rate of H-Ara-C uptake, 
from a control (DAU(5/*M-3 hrs) alone) value of 3.4 to 4.4 
for 5j«M PF(p 0.01) and 4.6 for 10/*M PF(p=0.05). The effect 
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3 
of DAU concentration on the marked enhancement of H-Ara-C 
uptake exhibited by DAU and PF sequenced pretreatment is 
shown in Figure 9. Slight increases in rate for l/*-M and 
3>*M DAU (2,5 and 3.4, respectively, vs. a control (PF(5juJl- 
3 hrs) alone) value of 2.4) became significant increases 
3 
in the rate of H-Ara-C accumulation at DAU concentrations 
of (rate-4.4, p<0.001) and 10>tM (rate=4.6, p<.0.025). 
Reversing the order of pretreatment markedly 
3 
alters the effect of PF and DAU pretreatment on H—Ara—C 
uptake, as presented in Figure 10. Intracellular accumulation 
is significantly higher when DAU precedes PF than when PF 
precedes DAU (p<0.01), with the latter resulting in a rate 
of uptake similar to that of DAU pretreatment alone. 
The results of the uptake experiments are sum¬ 
marized in Figure 10 and Table 4. 
Table 4 t ^IT—Ara—C Uptake 
Pretreataent 5 win.*_10 min, 15 win, 20 min. 60 min. 
A. Control(Ara-C 3^«M) 24.7 +8.8 37.3 +6.0 47.0 +9.1 59.7 +7.8 95.3 .+ 7.4 
B. DAU 5/<M (3 hrs) 25.8 +3.3 43.6 *3.9 60.3 +5.8A 76.7 +7.8A 116.1 +20.9 
C. PF 5/«M (3 hrs) 
25.3 +8.5 39.1 +9.5 51.3 +11.6 61.6 +.14.7 104.3 +29.5 
D. DAU 5/iM (3 hrs), « a 
PF 5*M (3 hrs) 39.7 +5.7® 60.4 +8.4® 82.8 ,+ 10.2@105.3 +9.3® 185.7 +48.8^ 
E. PF 5/iM (3 hrs), x A 
DAU 5/mM (3 hrs) 26.9 +3.3 42.9 +.3.8 60.8 +.6.3 75.7 +9.5 146.6 +41.7 
•-in «eles X 10“12/106cells, +. 1 Standard Deviation 
A 
-p<.05, compared to other treatments 
A-p<.05, compared to Control 
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C. Ribonucleotide Triphosphate Levels in HL-60 cells 
Table 5 and Figure 11 illustrate the changes 
in acid-soluble ribonucleotide TP pools in HL-60 cells 
subjected to DAU(5yM-3 hrs), PF(5yM-3 hrs), and/or 
3 
H-Ara-C(3yM-l hr). Control values were as follows: 
ATP-3080•4pmol/106cells, GTP-875.8, UTP-1328.8, CTP- 
555,9. DAU treatment reduced CTP to 5 7.8% of control; 
UTP and ATP were reduced to 73,4 and 70,4% of control, 
respectively. PF following DAU further reduced CTP to 
20,6% of control while reducing UTP to 28,7% of control 
in the face of ATP levels equal to control, PF alone 
reduced CTP to 28.6% and UTP to 20,7% of control, and 
subsequent DAU exposure further reduced CTP and UTP 
to 12.9 and 8.0 percent of control, respectively, with 
ATP levels about 80% of control in both cases, Ara-C 
alone reduced UTP and CTP levels to 60.9% and 78.9% 
of control, respectively, with modest reductions in 
ATP and GTP levels as well. This same effect was noted 
in cells pretreated with DAU then PF or PF alone. Cells 
treated with DAU alone had little change in NTP levels in 
response to Ara-C, and cells treated with PF then DAU 
responded with a modest increase in UTP and CTP (from 
8.0 to 15.0 and 12.9 to 16.1, respectively), with slight 
reductions in ATP and GTP. (Note: GTP measurements may 
be less accurate than those of the other NTPs because of 
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Figure 11: Nucleotide Triphosphate Peaks at 280 nm 
(see Table 5 for identification) 
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the difficulty of determining the end of the GTP peak) 
Table 6; Ribonucleotide Triphosphate Ratios 
(see Table 5 for identification) 
Sample CTP/UTP*^ CTP/ATP UTP/ATP 
-A. •42(1.0) .33(1.0) .43(1.0) 
1. • 33(.79) .15(.82) .45(1.0) 
C. •30(.72) •04(.21) •12(•29) 
D. • 35(.83) •03(.17) .09(.20) 
E. .58(1.4) •06(.36) • 11(•26) 
F. .67(1.6) •03(.15) •04(.09) 
G . .45(1.1) •04(.24) •1Q(.23) 
H. .30(.71) •12(.66) •40(*94) 
I. .90(2.2) .06(.33) .07(.16) 
J. .54(1.2) .15(.85) .28(•66) 
- Using values from Table 5* Figures in parentheses 
express ratios in terms of ratios of control cells. 
Relating the concentrations of CTP and UTP to 
each other and to ATP may shed some light on the effects 
of the drugs on HL-60 cells. As presented in Table 6, the 
CTP/UTP ratio yields the most new information. As expected, 
treatment with DAU alone lowered the CTP/UTP ratio (from 
•42 to .33, or 79% of control). Exposing these cells to 
PF, Ara-C, or both agents caused relatively little change 
in this ratio (compare ». to C., H., and D.). PF alone, 
on the other hand, increased the CTP/UTP ratio to .58 (140% 
of the control value), and subsequent DAU exposure did 
not reverse this effect. Treatment with Ara—C, noted above 
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to decrease UTP to a greater degree than CTP, enhanced 
this effect. Ara-C alone led to a CTP/UTP ratio of .54; 
in combination with PF the ratio rose to .90(220% of con¬ 
trol value). The possible effects of these changes in 
CTP/UTP ratios will be discussed below. 
D. Ara-CTP levels 
3 
After 1 hour exposure to 3 M H-Ara-C, 67.7% 
of the label recovered from the HPLC column eluted in the 
triphosphate region (Figure 12), between CTP and ATP peaks. 
The chromatogram of pure Ara-CTP identified this peak as 
Figure 12: Chromatogram of Ara-C Derivatives with 
Standard Chromatogram(inset) 
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Ara-CTP. Smaller peaks in the nucleotide di- and monophos¬ 
phate regions are likely Ara-CDP(7.1%) and Ara-CMP(1.6%), 
respectively. In this buffer system, unchanged Ara-C, 
present as 16.5% of total counts recovered from the column, 
elutes near the origin. It was discovered that perchloric 
acid precipitation through the application of the sample 
to the column resulted in a loss of almost 50% of the 
label compared to values from the uptake experiments, but 
all values for Ara-CTP below were calculated taking into 
account the decreased counting efficiency described in the 
Methods section, but without correction for the loss of 
label mentioned just above (since the Ara-CTP fraction of 
that loss is incalculable). 
Table 7: Ara-CTP levels and Ratio to CTP Level 
Treatment Ara-CTP • %Total Ara-C Ara-CTP/Cr 
Control** 31.5 35.6 5.67 
DAU 5yM(3 hrs) 45.2 33.0 14.02 
PF 5yM (3 hrs) 18.9 23.6 11.87 
DAU 5yM(3 hrs), 
PF 5yM(3 hrs) 33.6 18.0 29.29 
PF 5yM(3 hrs), 
DAU 5yM(3 hrs) 30.7 18.8 42.70 
*- in moles X 10 “12/106 cells 
& 
- expressed as percent of CTP level 
# 1 T 3 
- ail H-Ara-C exposures were 3yM-l hr 
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Table 7 presents the data on Ara-CTP levels for 
control and pretreated HL—60 cells* Whereas pretreatment 
with DAU markedly enhanced the formation of Ara-CTP, PF 
pretreatraent interfered with Ara-CTP formation, with the 
decline in actual level paralleled by a drop in percent total 
intracellular Ara-C recovered as the triphosphate (from 35.6% 
in control to 23.6% in PF pretreated cells). This effect was 
even more marked in cells pretreated with DAU and PF. In 
either order, total Ara-CTP was no greater than in control 
cells and reflected a cut in half of the percent total intra¬ 
cellular Ara-C recovered as Ara-CTP. 
The final column of Table 7 relates Ara-CTP con¬ 
centrations to CTP concentrations at the beginning of Ara-C 
exposure. The Ara-CTP/CTP ratio is doubled with PF pretreatment 
and two-and-a-half times control following DAU pretreatment, 
but the combination of the two drugs has a more marked effect. 
DAU followed by PF results in an Ara-CTP/CTP ratio five times 
control and PF followed by DAU results in a^ratio seven-and- 
a-half times control. Figure 13 relates this ratio to HL-60 
clone survival data for controls and pretreated cells and 
reveals a consistent (R =0.99) relationship between higher 
Ara-CTP/CTP ratios and enhanced cytotoxic effect. 
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Figure 13: Clone Survival as a function of the 
Ara—CTP/CTP ratio 
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IV. DISCUSSION 
These studies indicate that pretreatment of 
L1210 or HL-60 cells with PF then DAU sensitizes them to 
the cytotoxic effect of Ara-C, resulting in a synergistic 
decrease in the ability of the cells to form a clone. The 
mechanism of this synergy, in HL-60 cells, is apparently 
a marked increase in the Ara-CTP/CTP ratio compared to 
cells exposed to Ara-C without pretreatment. If, as sug¬ 
gested by earlier work, a reduction in CTP also depletes 
dCTP pools, these findings are consistent with a mechanism 
of Ara-CTP lethality in which Ara-CTP competes with dCTP. 
The reverse sequence, DAU then PF pretreatment, results 
in significantly higher uptake values, but because it is 
less effective at depleting CTP, the Ara-CTP/CTP ratio is 
lower, as is its ability to enhance Ara-C lethality. 
At the outset, three remarks are in order. First, 
the experiment strongly suggests that measurement of Ara-C 
uptake is not sufficient for relating the effect of a pre¬ 
treatment regimen to Ara-C toxicity. Because of different 
rates of phosphorylation and, even more important, the com¬ 
petitive nature of Ara-CTP toxicity, Ara-CTP levels and CTP 
or, better yet, dCTP levels must be measured. In addition, 
while much is made of dCTP inhibition of DCK^, the enzyme 
responsible for initial phosphorylation of Ara-C, as in¬ 
dicated on Table 1 UTP and dTTP exert an activating influence 
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on this enzyme, PF alone or combined PF and DAU pretreatment 
in either sequence depletes cellular UTP and, likely, dTTP. 
This explains both the inhibition of total uptake and the 
decline of percent Ara-CTP of total intracellular Ara-C 
with those pretreatment regimes, A corollary to this finding 
is that an elevated CTP/UTP ratio, such as seen after PF 
or PF then DAU pretreatment, would inhibit DCK^ to a greater 
degree than a depressed CTP/UTP ratio, such as seen after 
DAU then PF pretreatment, 
Finally, when studying the effects of a cell-cycle 
specific agent like Ara-C, one must pay attention to the 
length of the cell cycle in the cells being studied, L1210 
cells double approximately every 12 hours; HL-60 cells 
double approximately every 24 hours. Thus the likelihood 
of 'catching* a cell in S phase, either during the drug 
exposure or after the drug exposure at a time when Ara-CTP 
levels are still high enough to have a lethal effect is, 
disregarding different rates of Ara-CTP catabolism, roughly 
twice as great for L1210 than HL-60, a likely contribution 
to the higher order of cell kill for the mouse cells. The 
effect of cell cycle length on Ara-C toxicity is even more 
marked following pretreatment, especially if S phase or 
G^/S boundary synchronization is considered a contributing 
factor to the enhancement of Ara-C toxicity, as has been 
postulated for DAU and PF. In these experiments, relatively 
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short drug exposures were used to simulate the in vivo 
administration of a drug bolus, after which all of the 
agents being studied are cleared relatively quickly, though 
drug effects may last for some time. Continuous infusion 
therapy would obviously allow for higher drug levels over 
a longer period, and thus synchronize a larger portion of 
the cells, but would likely also increase toxic side effects, 
Ara-C uptake and Ara-CTP formation following 
Ara-C exposure without pretreatment in HL-60 cells, with 
Axa-CTP accounting for two-thirds of the intracellular 
Ara-C, are similar to those reported elsewhere (89), DAU 
pretreatment with for 3 hours modestly lowered CTP, 
relative to ATP, without affecting UTP. This, and perhaps 
inhibition of CD (35), enhanced Ara-C uptake and resulted 
in the highest levels of intracellular Ara-CTP. However, at 
this relatively low drug concentration for a much shorter 
drug exposure than used by earlier investigators (62,68,77), 
cytotoxic synergy was modest in HL-60 cells, though somewhat 
more impressive in L1210, The decline in CTP may not have 
been enough to significantly affect the dCTP pool, though 
the Ara-CTP/CTP ratio was two-and-a-half times control. 
If cell cycle arrest is a major determinant of cytotoxic 
enhancement for the DAU/Ara-C drug sequence, as suggested 
by Lauzon et ail. (68), the shorter drug exposure would 'trap' 
fewer cells in the Ara-C-sensitive S phase. Finally, the 
self-limited nature of DAU toxicity discussed in the intro- 

67 
duction may also limit its ability to enhance Ara-C le¬ 
thality 
PF inhibits OTD much more effectively than DAU 
does CTS and, at 5^.M for 3 hours, markedly depletes cellular 
UTP and CTP, with the former affected to a greater degree. 
This likely results in reduced dCTP as well, which, 
by itself, should enhance Ar^-C uptake and phosphorylation. 
However, as noted by other investigators (11,86), Ara-C 
uptake is not increased, and in these experiments Ara-CTP 
was just 60% of control. The effect of UTP depletion on 
DCK^ is a likely source of this discrepancy. The presence of 
marginally better than additive cytotoxicity in HL-bO cells 
treated with PF then Ara-C, and the synergy evident in L1210, 
is due to the doubling of the Ara-CTP/CTP ratio. This is 
likely the source for the marked enhancement of Ara-C in¬ 
corporation into DNA following PF pretreatment reported 
by Plagemann et a_l. (86) as well. Also, if, as suggested by 
Hill and Whelan (55), PF arrests cells in the S phase or at 
the G^/S boundary, the toxic effect of subsequent Ara-C 
exposure would be maximized. 
Pretreating with both drugs leads to marked re¬ 
ductions of both CTP and UTP, with the greatest depletion 
noted when PF is the first drug administered. With the 
reduction of DCK^ activation by UTP, while HL-60 cells 
exposed first to DAU had a significantly higher rate of 
Ara-C uptake than cells exposed first to PF, this occurred in 
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the absence of increased Ara-CTP formation, resulting in a 
lower Ara-CTP/CTP ratio for DAU then PF than PF then DAU. 
This paralleled the changes in HL-60 clone survival, as 
presented in Figure 13. This apparent intracellular accumu¬ 
lation of metabolites of Ara-C other than the triphosphate 
and/or the unchanged drug is of uncertain etiology, but it 
may well play a role in the levelling off of Ara-C uptake 
due to back-diffusion of substances such as Ara-U. At higher 
rates of uptake the enzymes which deaminate Ara-C and Ara-CMP 
to Ara-U and Ara-UMP may be activated, or accumulation of 
Ara-CMP and/or Ara-CDP may occur. Measuring Ara-U, Ara-UMP, 
Ara-CMP, and Ara-CDP levels could identify the Ara-C ’well.* 
Figure 13 illustrates a fairly straightforward 
relationship between the Ara-CTP/CTP ratio and the effects 
of DAU and PF pretreatraent on HL-60 clone survival, but 
enhancement of Ara—C toxicity may be more complex than sug¬ 
gested here. Recall the apparent inconsistency reported by 
Harkrader ejt al.(50), who found that while cells exposed to 
deoxyadenosine had a higher Ara-CTP level and a higher 
Ara—CTP/dCTP ratio than cells exposed to deoxyguanosine, 
whose Ara-CTP content was no higher than control cells, 
the latter had three times the Ara-C incorporation into 
DNA of controls while the former had only double the con¬ 
trol value. Deoxyguanosine also resulted in more marked 
synergy with Ara-C than deoxyadenosine. To resolve these 
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questions in regards to the agents in this study, deoxy- 
ribonucleotide levels and Ara-C incorporation into DNA 
should be measured. Perhaps rapid incorporation of Ara-C 
into DNA, with or without concurrent inhibition of DNA 
polymerase, affects cellular expression of the metabolic 
alterations characteristic of S phase. These alterations, 
as noted in the introduction, include increased uptake and 
phosphorylation of nucleosides and their analogs, including 
Ara-C, The picture is that of a cell critically depleted 
of dCTP following PF and DAU pretreatment, activating trans¬ 
port and DCK^ at the onset of S phase only to be greeted 
with a lethal relative concentration of Ara-CTP, shutting 
down the S phase processes. This would result in lower 
total Ara-CTP content, but might be revealed by plotting 
Ara-CTP/Total intracellular Ara-C against time exposed to 
Ara-C, 
Because of more marked UTP, CTP, and, likely, dTTP 
depletion following PF pretreatment, cell cycle synchroni¬ 
zation may be more marked than following DAU exposure. Thus, 
simply by lengthening the period of PF action from 3 to 
6 hours by putting it first in the sequence, more cells may 
be 'caught* in the S phase, - or released into the S phase, 
when Ara-C is administered. 
A final brief hypothesis is required to explain 
synergy between Ara-C and PF and/or DAU even when Ara-C 

70 
is the first drug administered. Cells may be able to re¬ 
pair the damage done to their DNA under the influence of 
Ara-C, either through its incorporation into DNA or al¬ 
tered DNA synthesis secondary to inhibition of DNA poly¬ 
merase. There is no evidence that Ara-C affects excision 
repair. However, the cell would require dCTP for normal 
repair, and if its synthesis is inhibited by PF or DAU, 
the cell will be unable to repair its DNA and may progress 
to cell death. 
In conclusion, this study has demonstrated the 
efficacy of a drug regimen involving PF then DAU pretreat¬ 
ment of L1210 and HL-60 cells exposed to Ara-C. By depleting 
cellular UTP, PF enhances the ability of DAU to block CTP 
synthesis, resulting in increased Ara-C uptake via removal 
of feedback inhibition of DCK^. A sevenfold elevation of the 
Ara-CTP/CTP ratio, perhaps accompanied by accumulation of 
cells in the S phase or at the G^/S boundary, results in 
synergistic enhancement of Ara-C cytotoxicity. Though further 
studies are undoubtedly necessary, I would urge the eventual 
application of this rationally-designed drug combination 
regimen to patients with tumors otherwise unresponsive. 
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